However, there is a need to understand the role of IKKα within the tumour and the tumour microenvironment (TME), as well as robust testing of preclinical IKKα inhibitors, and identification of which CRC patient populations could benefit from targeted inhibition before the clinical translation of IKKα inhibitors. This evidence concerns the gene CHUK and neoplasm.